NEW YORK — Goldman Sachs raised its price target for Roche Holdings AG to CHF 366 from CHF 349, while maintaining a Neutral rating on the Swiss pharmaceutical giant, analyst James Quigley wrote in a Tuesday note.
Goldman sees the company’s annual Pharma Day on September 28 as likely to deliver useful information but does not expect it to reshape the investment thesis, Quigley wrote. He anticipates no near-term shifts in consensus estimates, though he did adjust his own forecasts for the drug Giredestrant.
Roche (ISIN: CH1499059XXX) is listed on the SIX Swiss Exchange. The research was published on September 15, 2026.
The firm’s disclosure note references requirements under § 85 Abs. 1 WpHG and Art. 20 VO (EU) 596/2014 for conflicts of interest.
Separately, analysts at dpa-AFX flagged a growing energy bottleneck tied to the AI boom, noting that new data centers now require multiple gigawatts of power — comparable to several nuclear reactor blocks — intensifying competition for electricity capacity among hyperscalers locking in long-term supply agreements. Geopolitical risks around the Iran conflict and the Strait of Hormus further complicate the outlook, they wrote, suggesting power utilities and their suppliers could enter a prolonged upcycle driven by rising demand, contracted volumes, and escalating electricity prices.
